Myocardial Ischemic Reperfusion Injury Clinical Trial
Official title:
Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery
The aim of this trail is to assess the safety and therapeutic effects of single EPO intervention in different times during coronary surgery in changes of inflammatory response.
In addition to well-known effect of Erythropoietin (EPO) on erythropoiesis in hypoxic
conditions, some lines of evidence suggest its protective effects against reperfusion injury
in several tissues by its specific receptor.
Preclinical studies have indicated a broad variety of cardioprotective actions for EPO. It
improves cardiac function and exercise capacity in congestive heart failure, angiogenesis,
limit myocardial inflammatory response, cardiac remodeling, infarct size and apoptosis
extension induced by reperfusion injury. Activation of EPO receptor in endothelial and
cardiac cells is suggested to attenuate proinflammatory cytokines production and inflammatory
cells infiltration, and increasing nitric oxide production through possible mechanisms.
Reperfusion injury is unavoidable event during cardiac surgery using cardiopulmonary
bypass.It is associated with inflammation, cell injury and attenuate contractility property.
Although it is an area of concern and many clinical studies have been designed by different
interventions, it remains a major challenge. EPO intervention during heart reperfusion
(surgery/ percutaneous angioplasty) as a new promise of cardioprotection strategy is the main
design of several studies with conflicting results .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02149316 -
Remote Ischemic Preconditioning With Postconditioning in Heart Transplantation Surgery
|
N/A | |
| Completed |
NCT02405689 -
Myocardial Protection and Anesthetic Agents
|
Phase 4 |